$Aligos Therapeutics (ALGS.US)$ NEWS Aligos Therapeutics Pre...
NEWS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
The data shows that the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting.
The PK profile supports twice daily ritonavir-free dosing without a food effect.
Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.
The presentation highlights the best-in-class potential of ALG-097558 and its differentiation versus current standard of care coronavirus antiviral drugs.
Financial support for advancing ALG-097558 comes from various external funding sources, including government agencies.
The PK profile supports twice daily ritonavir-free dosing without a food effect.
Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.
The presentation highlights the best-in-class potential of ALG-097558 and its differentiation versus current standard of care coronavirus antiviral drugs.
Financial support for advancing ALG-097558 comes from various external funding sources, including government agencies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
510Followers
65Following
3197Visitors
Follow
Jaguar8OP : At least an option while we prescribe Paxlovid